Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | TERT | O14746 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6138108 | 0.83 | KMT2A (0.69) | KMT2AHSD17B10MAPK1NTSR1IDO1 | |
| SCHEMBL12605550 | 0.83 | KMT2A (0.59) | KMT2AHSD17B10MAPK1NTSR1IDO1 | |
| SCHEMBL31238628 | 0.82 | NTSR1 (0.56) | TERTATMNTSR1IDO1KDM4E | |
| SCHEMBL31602786 | 0.81 | KMT2A (0.65) | KMT2AHSD17B10MAPK1NTSR1IDO1 | |
| SCHEMBL1967792 | 0.78 | CDK4 (0.68) | KMT2ATERTHSD17B10MAPK1 | |
| SCHEMBL29560163 | 0.78 | CDK4 (0.68) | KMT2ATERTHSD17B10MAPK1 | |
| SCHEMBL1598786 | 0.77 | KMT2A (1.00) | KMT2AHSD17B10MAPK1NTSR1KDM4E | |
| SCHEMBL29420405 | 0.77 | KMT2A (1.00) | KMT2AHSD17B10MAPK1NTSR1KDM4E | |
| SCHEMBL1269116 | 0.77 | CDK4 (0.71) | KMT2ATERTHSD17B10MAPK1 | |
| SCHEMBL3307080 | 0.77 | KMT2A (0.68) | KMT2AHSD17B10MAPK1NTSR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368131-A1 | OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2024-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368131-A1 | OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | NLRP3, NLRP1, NOD1 | KMT2A 4759/4885TERT 4384/4885HSD17B10 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.